This study indicates that pharmacological inhibition of LH2 by SAB effectively disrupts collagen cross-linking and fibrotic progression, offering a promising therapeutic avenue for pulmonary fibrosis. The gene discussed is PLOD2; the disease is pulmonary fibrosis.